Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04185883 |
TitleSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | 阶段
第 1 阶段
|
Date Added 2019-12-04 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States 澳大利亚 Austria 比利时 加拿大 德国 意大利 日本 大韩民国 荷兰 西班牙 台湾 英国 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06850103 |
TitleSCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer with Oligometastases | 阶段
第二阶段
|
Date Added 2025-03-25 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06835179 |
TitleSBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | 阶段
第二阶段
|
Date Added 2025-02-19 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06794086 |
TitleSBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases | 阶段
第三阶段
|
Date Added 2025-01-27 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT03313778 |
TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors | 阶段
第 1 阶段
|
Date Added 2017-10-18 |
地点
Arizona, United States
California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States 澳大利亚 日本 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
mRNA-4157, Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT02617277 |
TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | 阶段
第 1 阶段
|
Date Added 2015-11-30 |
地点
Colorado, United States
Florida, United States Tennessee, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
AZD1775, MEDI4736 |
标签
MSS/ MMRp
|
| NCT ID NCT05243862 |
TitleSafety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | 阶段
第二阶段
|
Date Added 2022-02-17 |
地点
Arizona, United States
Florida, United States Minnesota, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab, PolyPEPI1018, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT06065371 |
TitleSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 阶段
第 1 阶段
|
Date Added 2023-10-03 |
地点
Michigan, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
capecitabine, Sacituzumab govetican |
标签
MSS/ MMRp
|
| NCT ID NCT03365882 |
TitleS1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | 阶段
第二阶段
|
Date Added 2017-12-07 |
地点
Alaska, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States 波多黎各 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta |
标签
MSS/ MMRp
|
| NCT ID NCT05733611 |
TitleRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | 阶段
第二阶段
|
Date Added 2023-02-17 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSS/ MMRp
|
